GlycoMimetics Inc. [GLYC] stock is down -2.89 while the S&P 500 has risen 0.09% on Monday, 12/07/20. While at the time of this article, GLYC ATR is sitting at 0.24, with the beta value at 2.47. This stock’s volatility for the past week remained at 5.56%, while it was 7.16% for the past 30-day period. GLYC has fallen -$0.11 from the previous closing price of $3.80 on volume of 0.42 million shares.
On 7, December 2020, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition. According to news published on Yahoo Finance, Open label study demonstrated statistically significant effects of early treatment with rivipansel on time to discharge and time to discontinuation of intravenous opioids.
Analyst Birdseye View:
The most recent analyst activity for GlycoMimetics Inc. [NASDAQ:GLYC] stock was on August 05, 2019, when it was Downgrade with a Hold rating from SunTrust, which also lowered its 12-month price target on the stock from $23 to $5. Before that, on November 14, 2019, ROTH Capital Recapitulated a Buy rating and elevated its amount target to $12. On August 05, 2019, Piper Jaffray Downgrade a Neutral rating and plunged its price target on this stock from $20 to $6. On August 05, 2019, Jefferies Downgrade a Hold rating. On April 12, 2019, Piper Jaffray Initiated an Overweight rating and increased its price target to $20. On December 18, 2018, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $24. On July 26, 2016, SunTrust Initiated a Buy rating. On March 17, 2015, Stifel Reiterated a Buy rating and amplified its amount target to $14.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.82 and a peak of $6.29. Right now, the middling Wall Street analyst 12-month amount mark is $12.00. At the most recent market close, shares of GlycoMimetics Inc. [NASDAQ:GLYC] were valued at $3.69.
The Principal structure of this organization shows its whole liability to whole principal at 2.30 and the whole liability to whole assets at 2.16. It shows enduring liability to the whole principal at 1.79 and enduring liability to assets at 0.02 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.70 points at 1st support level, the second support level is making up to 3.61. But as of 1st resistance point, this stock is sitting at 3.91 and at 4.03 for 2nd resistance point.
GlycoMimetics Inc. [GLYC] reported its earnings at -$0.29 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.33/share signifying the difference of 0.04 and 12.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.32 calling estimates for -$0.38/share with the difference of 0.06 depicting the surprise of 15.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for GlycoMimetics Inc. [NASDAQ:GLYC] is 14.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 14.45. Now if looking for a valuation of this stock’s amount to book ratio is 1.49.
The most recent insider trade was by BVF PARTNERS L P/IL, 10% Owner, and it was the purchase of 1.27 million shares on Nov 04. BVF PARTNERS L P/IL, the 10% Owner, completed a purchase of 0.93 million shares on Oct 30. On Mar 09, JUNIUS DANIEL M, Director, completed a purchase of 20000.0 shares.